{
  "docId": "019de077-880d-703f-ad59-c0ee1df8dfeb",
  "docSlug": "3a2edb97bafa9f0a0205c3f0e878214f",
  "documentTitle": "Legend Biotech | Investor Presentation Deck | 26 slides",
  "authorId": "legend-biotech",
  "authorName": "Legend Biotech",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 26,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": "Includes Kaplan-Meier survival curve and associated table for refractory patient groups.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/5",
  "deckHref": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb",
  "deckJsonHref": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json",
  "deckAnchorHref": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.42,
        "x": 0.55,
        "y": 0.08
      },
      "kind": "callout",
      "text": "POOR SURVIVAL OUTCOMES IN MULTIPLE REFRACTORY MM Median OS < 12 months in patients refractory to anti-CD38, ≥ 1 PI(s) and / or ≥ 1 IMiD(s)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b03ab9cd-64f4-4f41-8ac4-8ee0084ae563",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.55,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Kaplan-Meier survival curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "396adbd8-55ad-48e5-b68b-5f16e08e4e65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.33,
        "x": 0.12,
        "y": 0.55
      },
      "kind": "metric",
      "text": "187,952 NEW CASES WORLDWIDE IN 2022",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b04b4444-0c18-4014-a258-dae3b31fc64b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.48,
        "x": 0.03,
        "y": 0.37
      },
      "kind": "paragraph",
      "text": "3RD MOST COMMON BLOOD CANCER accounting for 10% of all hematologic cancer",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5145f27-7cce-4022-818f-4cbb6d954b74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "CI, confidence interval; PI, Proteasome Inhibitor; IMiD, immunomodulatory drug; MM, multiple myeloma; OS, overall survival. 1. Leukemia & Lymphoma Society... 2. Globocan 2022... 3. Gandhi UH, et al.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5eaf126-deff-4ea0-888b-5fc782b04657",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.69,
        "y": 0.037
      },
      "kind": "table",
      "text": "Median OS for each group: Non-triple-refractory 11.2, Triple-and quad-refractory 9.2, Penta-refractory 5.6",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a19a4516-78e2-4f7d-a381-67a4379b6f3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.38,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "title",
      "text": "Blood Cancer with a High Unmet Need",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "447afe34-fd6e-42c1-930b-f5394be73914",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.35,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Multiple Myeloma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52a4627c-7958-4cad-a20a-cb7736b2ec90",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "f6960b55-db7a-4b48-8862-c2309e11ca9f",
      "evidence": "Frames the disease as a high unmet need with poor survival outcomes.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 5,
      "from": 5,
      "beatId": "953160cd-55b8-42e3-8fe7-a47be848b35f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The problem statement is presented on page 5, discussing Multiple Myeloma.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6befefba-5647-4a98-bbe1-2b8634a8df40",
      "evidence": "The problem statement and geographic map slides emphasize the importance of addressing Multiple Myeloma.",
      "position": 0,
      "objective": "Highlight the need for new treatments for Multiple Myeloma",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 25,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867",
      "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.",
      "position": 1,
      "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}